Meta-analyses on Viral Hepatitis

Infectious Disease Clinics of North America

Volumn 23, Issue 2, 2009, Pages 315-330

  Gluud, Lise L ^a,b   Gluud, Christian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hepatitis A; Hepatitis B; Hepatitis C; Meta analyses; Randomized trials; Systematic reviews; Viral hepatitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CATECHIN; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; IMMUNOGLOBULIN; LAMIVUDINE; PEGINTERFERON; PLACEBO; RIBAVIRIN; THYMOMODULIN;

ACTIVE IMMUNIZATION; ACUTE HEPATITIS; ANOREXIA; ARTHRALGIA; CHRONIC HEPATITIS; COCHRANE LIBRARY; COUGHING; DEPRESSION; DIARRHEA; DISEASE TRANSMISSION; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EMBASE; GEOGRAPHY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; INFECTION RISK; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DISEASE; MEDLINE; METHODOLOGY; MYALGIA; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; PASSIVE IMMUNIZATION; PREVALENCE; QUALITY CONTROL; RANDOM ERROR; RANDOMIZATION; RASH; REPEATED DRUG DOSE; REPRODUCIBILITY; REVIEW; RISK REDUCTION; SAMPLE SIZE; SAMPLING ERROR; SECONDARY PREVENTION; SKIN DISEASE; SOCIOECONOMICS; SYSTEMATIC ERROR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOTHERAPY; META-ANALYSIS AS TOPIC; TREATMENT OUTCOME; VACCINATION;

EID: 65249159179     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.01.005     Document Type: Review

References (74)

1. Gluud L.L. Bias in clinical intervention research. Am J Epidemiol 163 (2006) 493-501
2. Wood L., Egger M., Gluud L.L., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336 (2008) 601-605
3. Brok J., Thorlund K., Gluud C., et al. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 61 (2008) 763-769
4. Wetterslev J., Thorlund K., Brok J., et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61 (2008) 64-75
5. Kjaergard L.L., Frederiksen S.L., and Gluud C. Validity of randomized clinical trials in gastroenterology from 1964-2000. Gastroenterology 122 (2002) 1157-1160
6. Kjaergard L.L., Nikolova D., and Gluud C. Randomized clinical trials in hepatology: predictors of quality. Hepatology 30 (1999) 1134-1138
7. Shapiro C.N., and Margolis H.S. World-wide epidemiology of hepatitis A virus infection. J Hepatol 18 (1993) S11-S14
8. Bell B.P., Kruszon-Moran D., Shapiro C.N., et al. Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 23 (2005) 5798-5806
9. Ansaldi F., Bruzzone B., Rota M.C., et al. Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol 23 (2008) 45-53
10. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 56 (2007) 1080-1084
11. American Academy of Pediatrics Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics 120 (2007) 189-199
12. Bianco E., De Masi S., Mele A., et al. Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. Dig Liver Dis 36 (2004) 834-842
13. Victor J.C., Monto A.S., Surdina T.Y., et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 357 (2007) 1685-1694
14. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006) 529-538
15. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
16. Lai C.L., and Yuen M.E. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 147 (2007) 58-61
17. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
18. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
19. Chen G., Lin W., Shen F., et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 101 (2006) 1797-1803
20. Hoofnagle J.H., Doo E., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
21. Torbenson M., Kannagai R., Astemborski J., et al. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39 (2004) 51-57
22. Lok A.S., and Lai C.L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 8 (1988) 1130-1133
23. Yao J.L. Perinatal transmission of hepatitis B virus infection and vaccination in China. Gut 38 (1996) S37-S38
24. Lee C., Gong Y., Brok J., et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332 (2006) 328-336
25. Lee C., Gong Y., Brok J., et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2 (2006) CD004790
26. Chen W., and Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 4 (2005) CD000100
27. Greenberg H.B., Robinson W.S., Knauer C.M., et al. Hepatitis B viral markers in severe viral hepatitis: influence of steroid therapy. Hepatology 1 (1981) 54-57
28. Gregory P.B., Knauer C.M., Kempson R.L., et al. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med 294 (1976) 681-687
29. Schomerus H., Wiedmann K.H., Dölle W., et al. (+)-Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. Hepatology 4 (1984) 331-335
30. Galli M., Crocchiolo P., Negri C., et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res 11 (1985) 665-669
31. Kumar M., Satapathy S., Monga R., et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 45 (2007) 97-101
32. de Franchis R., Hadengue A., Lau G., et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 (2003) S3-S25
33. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 34 (2001) 1225-1241
34. Tompkins W.A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 19 (1999) 817-828
35. Wong D.K., Cheung A.M., O'Rourke K., et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 119 (1993) 312-323
36. Lok A.S., Wu P.C., Lai C.L., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102 (1992) 2091-2097
37. Brook M.G., Karayiannis P., and Thomas H.C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10 (1989) 761-763
38. Thomas H.C., Karayiannis P., and Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol 13 (1991) S4-S7
39. Bailon P., Palleroni A., Schaffer C.A., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12 (2001) 195-202
40. Cooksley W.G., Piratvisuth T., Lee S.D., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
41. Hui A.Y., Chan H.L., Cheung A.Y., et al. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 22 (2005) 519-528
42. Zhao H., Kurbanov F., Wan M.B., et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 44 (2007) 541-548
43. Lampertico P., Del Ninno E., Manzin A., et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26 (1997) 1621-1625
44. Fattovich G., Farci P., Rugge M., et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15 (1992) 584-589
45. Hadziyannis S., Bramou T., Makris A., et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 11 (1990) S133-S136
46. Pastore G., Sanantonio T., Milella M., et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 14 (1992) 221-225
47. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
48. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
49. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
50. Santantonio T., Mazzola M., Iacovazzi T., et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32 (2000) 300-306
51. Schalm S.W., Heathcote J., Cianciara J., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46 (2000) 562-568
52. Schiff E.R., Dienstag J.L., Karayalcin S., et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 38 (2003) 818-826
53. van Nunen A.B., Hansen B.E., Suh D.J., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52 (2003) 420-424
54. Hadziyannis S.J., and Papatheodoridis G.V. Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J Hepatol 39 Suppl 1 (2003) S172-S176
55. Shepherd J., Jones J., Takeda A., et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 10 (2006) iii-xiv 1
56. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
57. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
58. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
59. Rudin D., Shah S.M., Kiss A., et al. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 27 (2007) 1185-1193
60. Kaymakoglu S., Oguz D., Gur G., et al. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrobial Agents Chemother 51 (2007) 3020-3022
61. Alberti A., Vario A., Ferrari A., et al. Review article: chronic hepatitis C-natural history and cofactors. Aliment Pharmacol Ther 22 (2005) 74-78
62. Alter M.J. Prevention of spread of hepatitis C. Hepatology 35 (2002) S93-S98
63. Seeff L.B. Natural history of hepatitis C. Am J Med 107 (1999) 10S-15S
64. Consensus statement. EASL International Consensus Conference on Hepatitis C. J Hepatol 30 (1999) 956-961
65. Booth J.C., O'Grady J., and Neuberger J. The Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 49 (2001) 11-21
66. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
67. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 31 (1999) 54-60
68. Myers R.P., Regimbeau C., Thevenot T., et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 4 (2001) CD000370
69. Poynard T., Regimbeau C., Myers R.P., et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 1 (2002) CD000369
70. Myers R.P., Regimbeau C., Thevenot T., et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev (2002) CD000370
71. Brok J., Gluud L.L., and Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 101 (2006) 842-847
72. Kjaergard L.L., Krogsgaard K., and Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 323 (2001) 1151-1155
73. Brok J., Gluud L.L., and Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med 165 (2005) 2206-2212
74. Simin M., Brok J., Stimac D., et al. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 25 (2007) 1153-1162